Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...

AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 6 wks

First-in-human trial primes immune system to accept donor livers / 6 wks

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks

Keratin 16 restrains skin inflammation and may guide treatments / 7 wks

Avalyn upsizes IPO to raise cash for lung drug trials / 29 days

New science pushes erectile disorder treatment beyond Viagra / 4 wks

Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 wks